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Abstract
Background: The World Health Organization currently recommends combined streptomycin and rifampicin antibiotic
treatment as first-line therapy for Mycobacterium ulcerans infections. Alternatives are needed when these are not tolerated
or accepted by patients, contraindicated, or neither accessible nor affordable. Despite in vitro effectiveness, clinical evidence
for fluoroquinolone antibiotic use against Mycobacterium ulcerans is lacking. We describe outcomes and tolerability of
fluoroquinolone-containing antibiotic regimens for Mycobacterium ulcerans in south-eastern Australia.
Methodology/Principal Findings: Analysis was performed of prospectively collected data including all primary
Mycobacterium ulcerans infections treated at Barwon Health between 1998 and 2010. Medical treatment involved antibiotic
use for more than 7 days; surgical treatment involved surgical excision of a lesion. Treatment success was defined as
complete lesion healing without recurrence at 12 months follow-up. A complication was defined as an adverse event
attributed to an antibiotic that required its cessation. A total of 133 patients with 137 lesions were studied. Median age was
62 years (range 3–94 years). 47 (34%) had surgical treatment alone, and 90 (66%) had combined surgical and medical
treatment. Rifampicin and ciprofloxacin comprised 61% and rifampicin and clarithromycin 23% of first-line antibiotic
regimens. 13/47 (30%) treated with surgery alone failed treatment compared to 0/90 (0%) of those treated with
combination medical and surgical treatment (p,0.0001). There was no difference in treatment success rate for antibiotic
combinations containing a fluoroquinolone (61/61 cases; 100%) compared with those not containing a fluoroquinolone (29/
29 cases; 100%). Complication rates were similar between ciprofloxacin and rifampicin (31%) and rifampicin and
clarithromycin (33%) regimens (OR 0.89, 95% CI 0.27–2.99). Paradoxical reactions during treatment were observed in 8 (9%)
of antibiotic treated cases.
Conclusions: Antibiotics combined with surgery may significantly increase treatment success for Mycobacterium ulcerans
infections, and fluoroquinolone combined with rifampicin-containing antibiotic regimens can provide an effective and safe
oral treatment option.
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Introduction
In recent years the treatment of Mycobacterium ulcerans (M.
ulcerans) has radically changed, evolving from a predominantly
surgically [1,2] to a predominantly medically treated disease [3].
This resulted from clinical experience supported by scientific data
showing superior outcomes when antibiotics were used alone [4,5],
or combined with surgery [6,7]. It is also supported by in vitro
data [8–10] of antibiotic effectiveness against M. ulcerans. The
World Health Organization now recommends combined strepto-
mycin and rifampicin antibiotic treatment as first-line therapy for
M. ulcerans infections, with surgery reserved mainly to remove
necrotic tissue, cover skin defects, and correct deformities [11].
The Bellarine Peninsula in south-eastern Australia has been
experiencing an epidemic of M. ulcerans since 1998. It affects local
residents, but also visitors from outside the endemic region, with
cases in those living locally managed at the local referral health
service, Barwon Health. In our region, despite recommendations
at the time against their use, adjunctive antibiotic treatment of M.
ulcerans was initiated from 1998 in response to severe disease
causing significant morbidity and requiring reconstructive
surgery, and disease recurrences despite surgery. Fluoroquino-
lones (FQ) were introduced into antibiotic regimens in 2003
[6,12] in response to perceived treatment failures and excess
toxicity with other antibiotics, as well as their potential
advantages in treating M. ulcerans; documented in vitro evidence
of activity [9,10,13–15], good bioavailability [16], and excellent
bone and tissue penetration [17]. Since their introduction they
have commonly been employed in the antibiotic regimens used at
Barwon Health.
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FQ antibiotics offer the possibility of completely oral antibiotic
regimens when combined with another active oral antibiotic,
usually rifampicin. This can be especially useful where other
recommended antibiotics are not tolerated, accepted, accessible, or
affordable. However, although there is evidence of good activity
against M. ulcerans in the laboratory [9–10,13], in mouse footpad
models [8,14,18], and small numbers of clinical cases [6,12,19–21],
clinical evidence of FQ efficacy is lacking. Therefore we undertook a
study during the current epidemic in the Bellarine Peninsula to
describe the use of FQ antibiotics in M. ulcerans treatment and to
compare their outcomes and tolerability with other antibiotics used.
Methods
Participants
Analysis was performed using prospectively collected data from
an electronic database containing information on all cases of M.
ulcerans infection treated at Barwon Health between 1st March
1998 and 31st May 2010. Data collected includes epidemiological
details, diagnostic tests, clinical features, treatment, and outcomes.
Only first lesions on initial presentation were analyzed to avoid
potential confounders when analyzing recurrent cases. Data was
analyzed anonymously.
Definitions
A case of M. ulcerans was defined as the presence of a lesion
clinically suggestive of M. ulcerans plus any of (1) a culture of M.
ulcerans from the lesion, (2) a positive PCR from a swab or biopsy of
the lesion [22], or (3) histopathology of an excised lesion showing a
necrotic granulomatous ulcer with the presence of acid-fast bacilli
consistent with acute M. ulcerans [23].
Surgical treatment was defined as the surgical excision of a
lesion. Due to the paucity of cases managed without surgery, only
those undergoing surgery were included. Major surgery involved
the use of a split thickness skin graft or a vascularized tissue flap to
Author Summary
Buruli ulcer is a necrotizing infection of skin and subcuta-
neous tissue caused by Mycobacterium ulcerans and is the
third most common mycobacterial disease worldwide (after
tuberculosis and leprosy). In recent years its treatment has
radically changed, evolving from a predominantly surgically
to a predominantly medically treated disease. The World
Health Organization now recommends combined strepto-
mycin and rifampicin antibiotic treatment as first-line
therapy for Mycobacterium ulcerans infections. However,
alternatives are needed where recommended antibiotics
are not tolerated or accepted by patients, contraindicated,
or not accessible nor affordable. This study describes the
use of antibiotics, including oral fluoroquinolones, in the
treatment of Mycobacterium ulcerans in south-eastern
Australia. It demonstrates that antibiotics combined with
surgery are highly effective in the treatment of Mycobac-
terium ulcerans. In addition, oral fluoroquinolone-containing
antibiotic combinations are shown to be as effective and
well tolerated as other recommended antibiotic combina-
tions. Fluoroquinolone antibiotics therefore offer the
potential to provide an alternative oral antibiotic to be
combined with rifampicin for Mycobacterium ulcerans
treatment, allowing more accessible and acceptable, less
toxic, and less expensive treatment regimens to be
available, especially in resource-limited settings where the
disease burden is greatest.
Figure 1. Type of treatment for initial M. ulcerans lesions.
doi:10.1371/journal.pntd.0001473.g001
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close the tissue defect, whereas minor surgery involved excision
plus primary closure of the defect. A positive margin was defined
on histology as granulomatous inflammation or necrotic tissue
extending to the margins of the excised lesion.
Medical treatment was defined as the use of antibiotics for more
than 7 days, and first-line regimens were the initial antibiotic
regimens used. A complication was an adverse event attributed to
an antibiotic that required the cessation of that medication. Drug
dosages for adults included ciprofloxacin 500 mg twice daily,
moxifloxacin 400 mg daily, rifampicin 10 mg/kg/day (up to a
maximum of 600 mg daily), clarithromycin 500 mg twice daily,
and amikacin 15 mg/kg/day.
Treatment success was defined as complete healing of the lesion
without recurrence 12 months after treatment commencement.
Treatment failure was defined as those who had a recurrence with
in at least 12 months of follow-up. Recurrence was defined as a
new lesion appearing either in the wound, locally, or in another
part of the body after the surgical excision of the initial lesion that
met the case definition for M. ulcerans. Paradoxical reactions were
not considered a recurrence and were defined as: initial clinical
improvement followed by the clinical deterioration of the treated
lesion, or the appearance of a new lesion, either locally or in a
distant body site, that on histopathology showed evidence of an
intense immunological reaction consistent with an immune-
mediated paradoxical reaction [19].
There was no standardized treatment protocol for M. ulcerans
followed in Barwon Health during the study period. The role of
surgery and the use of antibiotics were determined by individual
specialist practitioners involved in M. ulcerans treatment. Patients
were followed up according to routine clinical practice and
observed antibiotic complications recorded in clinical notes when
they occurred.
Ethics
This study was approved by the Barwon Health Research and
Ethics Committee.
Statistics
Data were collected and analysed with Epi-Info 6 (Centers for
Disease Control, Atlanta). Statistical significance was determined
using the 2-tailed Fisher exact test for 262 tables for each of the
categorical values. A non-parametric cumulative failure graph
using the Kaplan-Meier method and the endpoint of antibiotic
cessation was plotted using the statistics package Minitab (version
15) to model the proportion of antibiotics ceased over time due to
complications.
Results
One hundred and forty seven patients with M. ulcerans were
diagnosed and treated at Barwon Health over the study period 1st
March 1998 to 31st May 2010. Fourteen were excluded from
further analysis: 1 had no surgery, 2 died before the completion
of follow-up (1 from a cerebrovascular accident 52 days and 1 of
sepsis secondary to the M. ulcerans lesion 5 days post treatment
commencement), 1 was lost to follow-up 85 days post treatment
commencement, and for 10 treatment and follow-up was
ongoing. Therefore a total of 133 patients with 137 lesions (4
patients had 2 lesions at initial presentation) were included in the
analysis.
Median age of patients was 62 years (range 3–94 years); 7 (5%)
were ,15 years. Sixty-seven (50%) were male. Associated co-
morbidities included diabetes mellitus (11), malignancy (5),
connective tissue disease (4), and immunosuppressive treatment (4).
For 122 cases where the clinical type of lesion was recorded, 106
(87%) were ulcers, 9 (7%) were nodules, and 7 (6%) were
oedematous lesions. Diagnosis was made by PCR in 116 (87%),
positive culture in 22 (17%), and consistent histopathology in 54
(41%) cases. Eighteen of 24 (75%) PCR positive cases where
culture was performed were culture positive, but no cases were
culture positive and PCR negative. One case was PCR negative
but positive on histopathology.
Forty-seven (34%) lesions were treated with surgical excision
alone, and 90 (66%) had surgical excision and adjunctive antibiotic
therapy. To close the skin defect after excision of the lesion, 65
(47%) required a split thickness skin graft and 16 (12%) required a
vascularized tissue flap. The proportion of cases receiving
antibiotics significantly increased pre 2005 compared to post
2005, rising from 45% to 74% [,2005 18/40, $2005 72/97, OR
3.52 (1.52–8.20)] (Figure 1).
The most common initial antibiotic regimens were rifampicin
and ciprofloxacin (61%) and rifampicin and clarithromycin (23%).
Four patients received ciprofloxacin and clarithromycin, and 2
Table 1. First-line antibiotic regimens and complication rates.
Antibiotic regimen
First-line
(n=90) Complication
Rifampicin and ciprofloxacin 55 (61%) 17 (31%)
Rifampicin and clarithromycin 21 (23%) 7 (33%)
Rifampicin, clarithromycin, and ethambutol 5 (4%) 2 (40%)
Ciprofloxacin and clarithromycin 4 (4%) 0 (0%)
Rifampicin and moxifloxacin 2 (2%) 1(50%)
Clarithromycin and ethambutol 1 (1%) 0(0%)
Rifampicin, ethambutol, and amikacin 1 (1%) 1(100%)
Clarithromycin 1 (1%) 0 (0%)
doi:10.1371/journal.pntd.0001473.t001
Table 2. Proportion of cases with treatment success for all initial M. ulcerans lesions.
Total antibiotics+no antibiotics Received antibiotics No antibiotics P-value
All first episodes 123/137 (90%) 90/90 (100%) 33/47 (70%) p,0.0001
Minor surgery 53/59 (90%) 30/30 (100%) 23/29 (79%) p = 0.01
Major surgery 70/78(90%) 60/60 (100%) 10/18 (56%) p,0.0001
Negative margins 64/68 (94%) 35/35 (100%) 29/33 (88%) p = 0.05
Positive margins 59/69 (86%) 55/55 (100%) 4/14 (29%) p,0.0001
doi:10.1371/journal.pntd.0001473.t002
Fluoroquinolone Treatment Mycobacterium ulcerans
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patients received rifampicin and moxifloxacin regimens (Table 1).
FQ antibiotics were used in 3 of 5 children aged ,15 years who
received antibiotics. Antibiotics were given for a median duration
of 76 days (range 12–155 days); 21 (23%) between 12–30 days, 18
(20%) 31–60 days, 30 (33%) 61–90 days, 14 (16%) 91–120 days,
and 7 (8%) 121–155 days. FQ antibiotics were not used in this
study until 2004, but from then 82% of regimens were FQ
containing.
Fourteen of 47 (30%) of those treated with surgery alone failed
treatment compared to 0/90 (0%) of those treated with a
combination of medical and surgical treatment (p,0.0001). The
risk of treatment failure increased significantly with no antibiotics
compared to those treated with antibiotics for major surgery
(p,0.0001), minor surgery (p = 0.01), positive margins
(p,0.0001), and negative margins (p = 0.05) (Table 2). If minor
surgery and negative margins were present, 1/22 (5%) failed
treatment. If only regimens containing an FQ (n= 64) are
compared with surgery alone, the risk of treatment failure
remained significantly increased when no antibiotics were used
overall (p,0.0001) and for major surgery (p,0.0001) and positive
margins (p,0.0001) (Table 3). There was no difference in
treatment success rate for antibiotic combinations containing an
FQ (61/61 cases; 100%) compared with those not containing an
FQ (29/29 cases; 100%). Treatment success rates with antibiotics
were also similar pre-2004 when no FQs were used (11/11; 100%)
compared with post 2004 (79/79; 100%). All four cases treated
with ciprofloxacin and clarithromycin combined with surgery
experienced treatment success.
For those failing treatment, the recurrences occurred a median
90 days post surgery (range 14–300 days). In 9 (64%) patients this
was local and in 6 (43%) patients it was distant (1 had both).
Paradoxical reactions occurred in 8/90 (9%) of cases given
antibiotics after a median duration of 48 days (range 14–85 days).
Fifty-eight (64%) patients had antibiotics prior to surgery for a
median duration of 8 days (range 1–36 days). Of these,
mycobacterial cultures were performed on 28 excised specimens.
Cultures were positive for M. ulcerans in 11/20 (55%) of those who
received#14 days of antibiotics prior to surgery, and in 1/8 (12.5%)
of those who received .14 days of antibiotics prior to surgery
(Table 4). All cases with positive cultures were associated with
successful outcomes after a median antibiotic duration of 87 days
(range 30–155 days).
Rifampicin was associated with a complication in 19/85 (22%)
cases occurring at a median 27 days (range 6–94 days) and
involved gastrointestinal intolerance in 15, hepatitis 4, rash 3, and
hypoglycemia in 1 case. Ciprofloxacin was associated with a
complication in 13/63 (21%) cases occurring at a median 24 days
(range 6–90 days) and involved gastrointestinal intolerance in 10,
joint or tendon effects in 3, rash in 2, and hallucinations in 1 case.
Clarithromycin was associated with a complication in 10/38 (26%)
cases occurring at a median 25 days (range 2–60 days) and
involved gastrointestinal intolerance in 9, hepatitis in 1, and
palpitations in 1 case.
By 120 days on treatment, the proportion of cases in which
rifampicin [28.6% (95% CI 16.0, 41.2)], clarithromycin [29.4%
(95% CI 13.8, 45.0)], and ciprofloxacin [24.9% (95% CI 12.3,
37.5)] were ceased were similar (Figure 2), and complication rates
were similar between ciprofloxacin and rifampicin 17/55 (31%)
and rifampicin and clarithromycin 7/21 (33%) regimens (OR
0.89, 95% CI 0.27–2.99).
Table 3. Proportion of cases with treatment success for initial M. ulcerans lesions using fluoroquinolone-containing regimens.
Total antibiotics+no antibiotics Received antibiotics No antibiotics P-value
All first episodes 97/111 (87%) 64/64 (100%) 33/47 (70%) p,0.0001
Minor surgery 43/49 (88%) 20/20 (100%) 23/29 (79%) p = 0.07
Major surgery 54/62 (87%) 44/44 (100%) 10/18 (56%) p,0.0001
Negative margins 51/55 (93%) 22/22 (100%) 29/33 (88%) p = 0.14
Positive margins 44/54 (81%) 40/40 (100%) 4/14 (29%) p,0.0001
doi:10.1371/journal.pntd.0001473.t003
Table 4. Mycobacterial culture results for specimens after .14 days of antibiotics prior to surgical excision.
Antibiotic regimen
Antibiotic duration prior
to culture (days) Mycobacterial Culture
Total antibiotic
duration (days) Outcome
RCCp 18 Negative 23 Treatment success
RCp 20 Negative 132 Treatment success
RCp 33 Negative 90 Treatment success
RCp 36 Positive 119 Treatment success
RCp 41 Negative 88 Treatment success
RC 46 Negative 62 Treatment success
RCEA 65 Negative 65 Treatment success
RCCp 86 Negative 137 Treatment success
R = rifampicin, C = clarithromycin, Cp = ciprofloxacin, E = ethambutol, A = amikacin.
doi:10.1371/journal.pntd.0001473.t004
Fluoroquinolone Treatment Mycobacterium ulcerans
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Discussion
Our study demonstrates that, combined with surgical excision of
M. ulcerans lesions, antibiotics appear highly effective at preventing
disease recurrences; we describe a reduction of recurrence rates
from more than one quarter of cases with surgery alone to none if
antibiotics are used. This includes 64 cases treated with FQ-
containing regimens (the majority involving ciprofloxacin) which
show similar efficacy to non-FQ containing regimens. Recent
studies have provided strong evidence that non-FQ-containing
antibiotic regimens were effective in M. ulcerans treatment; 8-week
combinations of rifampicin and streptomycin cured 96% of cases
in a randomized controlled trial in Africa [5], and 8 weeks of
rifampicin and clarithromycin were 100% effective in an
uncontrolled trial in Benin [4]. Although we have previously
published small numbers of M. ulcerans cases treated with FQ-
containing regimens [6,12,19], this is the first study large enough
to provide significant evidence of the clinical effectiveness of FQ
antibiotics combined mainly with rifampicin in M. ulcerans
treatment.
Ciprofloxacin has been shown to have good in vitro activity
against M. ulcerans with minimal inhibitory concentrations (MIC)
of between 0.5 and 1 mg/l in two published studies [9,15]; in the
same studies these MICs compared favorably against the MICs of
currently recommended antibiotics (rifampicin 1–2 mg/l, amika-
cin 1 mg/l, clarithromycin 1 mg/l). Ciprofloxacin has also been
shown to have rapid bactericidal activity in humans against M.
tuberculosis [24–26], and has been used to successfully treat other
Figure 2. Proportion of individual antibiotics ceased over time due to complications.
doi:10.1371/journal.pntd.0001473.g002
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non-tuberculous mycobacterial infections including M. marinum
[27], the species most closely related to M. ulcerans. Moxifloxacin
similarly has good in vitro activity (MIC 0.25) [15]. In the mouse
footpad model, moxifloxacin has bactericidal activity against M.
ulcerans and, when combined with rifampicin, is as effective as
combinations of rifampicin/streptomycin, rifampicin/amikacin and
rifampicin/clarithromycin [8,18]. Furthermore, other factors that
favor the use of FQs include their high oral bioavailability (78%)
[16] and excellent bone and tissue penetration [17]. Nevertheless,
we would caution that fluoroquinolones should not be used as
monotherapy for M. ulcerans treatment as there is the potential for
the development of resistance, as has been shown to occur when
FQs are used as monotherapy for M. tuberculosis [25]. Moxifloxacin
may be favoured over ciprofloxacin due to slightly better published
MICs against M. ulcerans, the evidence from the mouse footpad
models of which there is no similar published data for ciprofloxacin,
greater potential barrier to resistance if effects are similar to that in
M. tuberculosis [25], and once-daily administration. A constraint at
present is its significant increased cost compared to ciprofloxacin,
with a cost of $671 compared with $32 Australian dollars for an 8-
week treatment course at our institution.
In mouse footpad models, rifampicin has the greatest bactericidal
activity againstM. ulcerans [8,18], and thus is assumed to be the most
active and important antibiotic in vivo, though there are no human
studies of rifampicin monotherapy to confirm this. It is possible that
the second agent, including the FQs, act only as bacteriostatic
agents preventing the emergence of rifampicin resistance. Therefore
we recommend rifampicin as the first antibiotic choice, to be
combined with another agent. Our data indicate that FQs are an
appropriate combination choice, especially in cases where other
antibiotics such as clarithromycin or streptomycin are not tolerated,
accepted by patients, or accessible, or are contraindicated. FQs,
greatest advantage may be their potential to be combined with other
oral antibiotics such as rifampicin to provide completely orally
administered regimens in endemic settings. This allows outpatient
care to be provided close to patient homes and avoids daily
intramuscular injections, potentially increasing patient willingness
to present early for diagnosis and increase adherence to treatment.
Furthermore, ciprofloxacin is generically produced, reducing its
cost, and is readily available in many resource-limited settings.
Antibiotics were most commonly given for between 1 and 3
months (53%) in our cohort. A proportion of cases (21; 23%) had
successful outcomes with less than 30 days of treatment, although
55% of cases given less than 2 weeks of antibiotics remained
culture positive. One case remained positive after 36 days of
antibiotics but still achieved cure, reinforcing findings from
previous studies that a small proportion of cases may remain
culture positive after 1–2 months of antibiotics but still achieve
cure with at least 8 weeks of antibiotics [4,5]. The proportion of
patients receiving antibiotic treatment significantly increased from
2005 as it became apparent in patients treated at Barwon Health
that antibiotics were associated with a reduction in disease
recurrences and permitted more conservative surgery to be
performed [6].
The efficacy of treatment is also determined by the tolerance of
the antibiotic regimens. In our study there were no significant
differences in the tolerability of the 3 main oral antibiotic choices
of rifampicin, clarithromycin, and ciprofloxacin. In addition, the
complications mainly involved gastrointestinal intolerance with no
significant sequelae. This differs from the significant incidence of
serious adverse events previously described for alternative
antibiotics such as streptomycin [5,28] and amikacin [6]. It is
important to note that the complication rates were higher in our
study compared to studies from African populations [4,5,7]. This
is likely due to the older patient population in our cohort where
these medications are less well tolerated, especially from a gastro-
intestinal viewpoint, and there is more potential for drug
interactions. Nevertheless it underlines the importance of having
a number of oral antibiotic combinations available if first-line
antimicrobials need to be substituted on account of intolerance.
Finally, paradoxical reactions occurred in 9% of antibiotic
treated cases. To our knowledge this is the first published rate of
paradoxical reactions in a cohort of patients treated for M. ulcerans.
In our study the reactions occurred as early as 2 weeks and as late
as 3 months after antibiotics were commenced. Recently,
paradoxical reactions occurring after the cessation of antibiotics
have been described [29]. It is important that paradoxical
reactions are considered and recognized during treatment, and
distinguished from treatment failures, to avoid unnecessary
antibiotic regimens changes or further surgery [19].
There are a number of limitations to our study. First, it is an
observational cohort and thus there is the potential for unknown
confounders to have affected the results. Despite this possibility,
the treatment outcome results are highly significant. Second, some
of the infections acquired from the local endemic region occurred
in visitors to the region and were not managed by our health
service (Barwon Health) but in the health services where they live.
Although this may have introduced a selection bias, we feel it is
unlikely that this would have changed the findings of our study.
Third, all cases underwent surgical excision and therefore the
outcomes may not be applicable to cases where antibiotics alone
are used. We advocate for further randomized studies using FQ-
containing antibiotic regimens without curative surgery be
performed to provide further information.
In summary, antibiotics in combination with surgery may
significantly increase treatment success for M. ulcerans infections. In
addition, antibiotic regimens containing oral FQs combined with
rifampicin can provide an effective and safe treatment option and
should be further studied in the treatment of M. ulcerans.
Supporting Information
Checklist S1 Strobe checklist
(PDF)
Acknowledgments
We acknowledge the statistical support of Yu Zhang for the cumulative
failure graph describing antibiotic cessation due to complications (Figure 2).
Author Contributions
Conceived and designed the experiments: DOB AMD PC IH AH NDF
EA AW. Performed the experiments: DOB AMD PC IH AH NDF EA
AW MR. Analyzed the data: DOB. Wrote the paper: DOB EA NDF.
References
1. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K (1999)
Mycobacterium ulcerans infection. Lancet Sep 18;354(9183): 1013–8.
2. Sizaire V, Nackers F, Comte E, Portaels F (2006) Mycobacterium ulcerans
infection: control, diagnosis, and treatment. The Lancet infectious diseases
May;6(5): 288–96.
3. Johnson PD (2010) Should antibiotics be given for Buruli ulcer? Lancet Feb
20;375(9715): 618–9.
4. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral
treatment for Mycobacterium ulcerans infection: results from a pilot study in
Benin. Clin Infect Dis Jan;52(1): 94–6.
Fluoroquinolone Treatment Mycobacterium ulcerans
www.plosntds.org 6 January 2012 | Volume 6 | Issue 1 | e1473
5. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010)
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a
randomised controlled trial. Lancet Feb 20;375(9715): 664–72.
6. O’Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, et al. (2007)
Outcomes for Mycobacterium ulcerans infection with combined surgery and
antibiotic therapy: findings from a south-eastern Australian case series. The
Medical journal of Australia Jan 15;186(2): 58–61.
7. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007)
Promising clinical efficacy of streptomycin-rifampin combination for treatment
of buruli ulcer (Mycobacterium ulcerans disease). Antimicrobial agents and
chemotherapy Nov;51(11): 4029–35.
8. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V (2006) In vitro
and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin,
R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial
agents and chemotherapy Jun;50(6): 1921–6.
9. Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MR, et al. (2000) In vitro
activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against
Ghanaian isolates of Mycobacterium ulcerans. The Journal of antimicrobial
chemotherapy 45(2): 231–3.
10. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of
new macrolides and fluoroquinolones against Mycobacterium ulcerans infection
in mice. Antimicrobial agents and chemotherapy 45(11): 3109–12.
11. World Health Orgainisation. Buruli Ulcer. [cited 2011 3rd June]; Available
from: http://www.who.int/buruli/information/antibiotics/en/index.html.
12. O’Brien DP, Athan E, Hughes A, Johnson PD (2008) Successful treatment of
Mycobacterium ulcerans osteomyelitis with minor surgical debridement and
prolonged rifampicin and ciprofloxacin therapy: a case report. Journal of
medical case reports 2: 123.
13. Dhople AM, Namba K (2002) In vitro activity of sitafloxacin (DU-6859a) alone,
or in combination with rifampicin, against Mycobacterium ulcerans. The
Journal of antimicrobial chemotherapy Nov;50(5): 727–9.
14. Dhople AM, Namba K (2003) Activities of sitafloxacin (DU-6859a), either singly
or in combination with rifampin, against Mycobacterium ulcerans infection in
mice. J Chemother 15(1): 47–52.
15. Saito HIN (2001) Antibacterial activities of new fluoroquinolones against
Mycobacterium Ulcerans. Journal of Antimicrobial Chemotherapy 47, suppl
2(May): Abstract P53.
16. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH (1992) Pharmaco-
kinetic profiles of ciprofloxacin after single intravenous and oral doses.
Antimicrobial agents and chemotherapy May;36(5): 993–6.
17. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V (1986)
Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicro-
bial agents and chemotherapy Mar;29(3): 405–8.
18. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V (2007) Orally administered
combined regimens for treatment of Mycobacterium ulcerans infection in mice.
Antimicrobial agents and chemotherapy Oct;51(10): 3737–9.
19. O’Brien DP, Robson ME, Callan PP, McDonald AH (2009) ‘‘Paradoxical’’
immune-mediated reactions to Mycobacterium ulcerans during antibiotic
treatment: a result of treatment success, not failure. The Medical journal of
Australia Nov 16;191(10): 564–6.
20. Phanzu DM, Ablordey A, Imposo DB, Lefevre L, Mahema RL, et al. (2007)
Short report: edematous Mycobacterium ulcerans infection (Buruli ulcer) on the
face: a case report. The American journal of tropical medicine and hygiene
Dec;77(6): 1099–102.
21. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, et al. (2010) All-
oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS
neglected tropical diseases 4(11): e770.
22. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, et al.
(1997) Development of a PCR assay for rapid diagnosis of Mycobacterium
ulcerans infection. J Clin Microbiol Jul;35(7): 1696–700.
23. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. (2003)
Histopathologic features of Mycobacterium ulcerans infection. Emerging
infectious diseases Jun;9(6): 651–6.
24. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, et al. (1993) Early
bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
The American review of respiratory disease Dec;148(6 Pt 1): 1547–51.
25. Gumbo T, Louie A, Deziel MR, Drusano G (2005) Pharmacodynamic evidence
that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but
to rapid emergence of resistance. Antimicrobial agents and chemotherapy
Aug;49(8): 3178–81.
26. Alangaden GJ, Lerner SA (1997) The clinical use of fluoroquinolones for the
treatment of mycobacterial diseases. Clin Infect Dis Nov;25(5): 1213–21.
27. Rallis E, Koumantaki-Mathioudaki E (2007) Treatment of Mycobacterium
marinum cutaneous infections. Expert opinion on pharmacotherapy Dec;8(17):
2965–78.
28. Chan-Tompkins NH (1995) Toxic effects and drug interactions of antimyco-
bacterial therapy. Clinics in dermatology May–Jun;13(3): 223–33.
29. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, et al. (2011)
Secondary Buruli ulcer skin lesions emerging several months after completion of
chemotherapy: paradoxical reaction or evidence for immune protection? PLoS
neglected tropical diseases Aug;5(8): e1252.
Fluoroquinolone Treatment Mycobacterium ulcerans
www.plosntds.org 7 January 2012 | Volume 6 | Issue 1 | e1473
